drugset / Trial / NCT01155141

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

NCT01155141 ↗

Phase 4 Completed 15 enrolled Stanford University Mallinckrodt · collab
NaSingle-groupOpen-labelTreatment

Summary

FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring. Corticosteroid therapy is occasionally, but not nearly universally, successful in reducing proteinuria, and when patients respond, they have a favorable prognosis. The investigators believe that ACTH therapy (H.P. Acthar Gel) can provide a more rapid, well tolerated reduction in glomerular injury.

Timeline

Start
2009-09
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject adrenocorticotropic hormone Unknown 80 iu Subcutaneous

Indications